Atypical antipsychotics in the EPS-vulnerable patient

Psychoneuroendocrinology

Volumn 28, Issue SUPPL. 1, 2003, Pages 39-51

  Friedman, Joseph H ^a  

^a MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

Atypical antipsychotic; Clozapine; Olanzapine; Parkinsonism; Quetiapine; Risperidone

Indexed keywords

ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

AGRANULOCYTOSIS; ARTICLE; CLINICAL TRIAL; DEMENTIA; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; GERIATRICS; HEMATOLOGICAL PARAMETERS; HUMAN; HYPOKINESIA; LOW DRUG DOSE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; PARKINSON DISEASE; PARKINSONISM; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME; VISUAL HALLUCINATION;

AGED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DYSKINESIA, DRUG-INDUCED; HUMANS; PARKINSON DISEASE, SECONDARY;

EID: 0037215368     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(03)00096-9     Document Type: Article

References (70)

1. Allen R.L., Walker Z., D'Ath P.J., Katona C.L. Risperidone for psychotic and behavioural symptoms in Lewy body dementia. Lancet. 346:1995;185.
2. Avorn J., Monane M., Everitt D.E., Beers M.H., Fields D. Clinical assessment of extrapyramidal signs in nursing home patients given antipsychotic medication. Arch. Intern. Med. 154:1994;1113-1117.
3. Breier A., Sutton V., Feldman P., Kadam D., Ferchland I., Wright P., Friedman J. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol. Psychiatry. 52:2002;438-446.
4. Churchyard A., Iansek R. Olanzapine as treatment of the neuropsychiatric complications of Parkinson's disease: an open-label study. Mov. Disord. 13:(Suppl. 2):1998;188.
5. De Deyn P.P., Rabheru K., Rasmussen A., Bocksberger J.P., Dautzenberg P.L., Eriksson S., Lawlor B.A. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 53:1999;946-955.
6. Evatt M.L., Jewart D., Juncos J.L. 'Seroquel' (ICI 204,636) treatment of psychosis in parkinsonism (letter). Mov. Disord. 11:1996;595.
7. Factor S.A., Molho E.S., Podskalny G.D., Brown D. Parkinson's disease: drug-induced psychiatric states. Weiner W.J., Lang A.E. Behavioral Neurology of Movement Disorders, Adv. in Neurology. vol. 65:1995;115-138 Raven Press, New York.
8. Factor S.A., Friedman J.H. The emerging role of clozapine in the treatment of movement disorders. Mov. Disord. 12:1997;483-496.
9. Fernandez H.H., Friedman J.H., Jacques C., Rosenfeld M. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov. Disord. 14:1999;484-487.
10. Fernandez H.H., Lannon M.C., Friedman J.H., Abbott B.P. Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov. Disord. 15:2000;579-581.
11. Ford B., Lynch T., Greene P. Risperidone in Parkinson's disease. Lancet. 344:1994;681.
12. Friedman J.H. The management of the levodopa psychoses. Clin. Neuropharmacol. 14:1991;283-295.
13. Friedman J.H. Lang A.F., Weiner M.J. Drug-Induced Parkinsonism in Drug-Induced Movement Disorders. 1992;Futura, New York.
14. Friedman J. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology. 50:1998;1195-1196.
15. Friedman J.H., Goldstein S., Jacques C. Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open label pilot study. Clin. Neuropharmacol. 21:1998;285-288.
16. Friedman J.H., Factor S.A. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov. Disord. 15:2000;201-211.
17. Goetz C.G., Tanner C.M., Klawans H.L. Pharmacology of hallucinations induced by long-term drug therapy. Am. J. Psychiatry. 139:1982;494-497.
18. Goetz C.G., Blasucci L.M., Leurgans S., Pappert E.J. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 55:2000;789-794.
19. Goldberg R.J., Goldberg J. Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience. Int. Psychogeriatr. 9:1997;65-68.
20. Graham J.M., Sussman J.P., Ford K.S., Sagar H.J. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note. J. Neurol. Neurosurg. Psychiatry. 65:1998;774-777.
21. Honigfeld G., Arellano F., Sethi J., Bianchini A., Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J. Clin. Psychiatry. 59:(Suppl. 3):1998;3-7.
22. Irizarry M.C., Ghaemi S.N., Lee-Cherry E.R., Gomez-Isla T., Binetti G., Hyman B.T., Growdon J.H. Risperidone treatment of behavioral disturbances in outpatients with dementia. J. Neuropsychiatry Clin. Neurosci. 11:1999;336-342.
23. Jeanblanc W., Davis Y.B. Risperidone for treating dementia-associated aggression. Am. J. Psychiatry. 152:1995;1239.
24. Jeste D.V., Glazer W.M., Morgenstern H., Pultz J.A., Yeung P.P. Rarity of persistent tardive dyskinesia with quetiapine treatment of psychotic disorders in the elderly (poster). Presented at the Annual Meeting of the American College of Neuropsychopharmacology, Acapulco, Mexico. 1999.
25. Jibson M.D., Tandon R. New atypical antipsychotic medications. J. Psychiatr. Res. 32:1998;215-228.
26. Jimenez-Jimenez F.J., Tallon-Barranco A., Orti-Pareja M., Zurdo M., Porta J., Molina J.A. Olanzapine can worsen parkinsonism. Neurology. 50:1998;1183-1184.
27. Juncos J.L., Evatt M.L., Jewert D. Long-term effects of quetiapine fumarate in parkinsonism complicated by psychosis. Neurology. 50:(Suppl. 4):1998;A70-A71.
28. Juncos J.L., Arvanitis L., Sweitzer D., Yeung P., Jewart R.D., Nemeroff C. Quetiapine improves psychotic symptoms associated with Parkinson's disease. Neurology. 52:(Suppl. 2):1999;A262.
29. Katz I.R., Jeste D.V., Mintzer J.E., Clyde C., Napolitano J., Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double blind trial. Risperidone Study Group. J. Clin. Psychiatry. 60:1999;107-115.
30. Kinon B.J., Lieberman J.A. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl). 124:1996;2-34.
31. Leopold N.A. Risperidone in patient's with parkinsonism. Mov. Disord. 13:(Suppl. 2):1998;78.
32. Love R.C., Nelson M.W. Pharmacology and clinical experience with risperidone. Expert Opin. Pharmacother. 1:2000;1441-1453.
33. Madhusoodanan S., Suresh P., Brenner R., Pillai R. Experience with the atypical antipsychotics - risperidone and olanzapine in the elderly. Ann. Clin. Psychiatry. 11:1999;113-118.
34. Markianos M., Hatzimanolis J., Lykouras L. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. Eur. Arch. Psychiatry Clin. Neurosci. 251:2001;141-146.
35. McKeith I.G., Ballard C.G., Harrison R.W. Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet. 346:1995;699.
36. McManus D.Q., Arvanitis L.A., Kowalcyk B.B. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. J. Clin. Psychiatry. 60:1999;292-298.
37. Meco G., Allesandri A., Bonifati V., Giustini P. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. Lancet. 343:1994;1370-1371.
38. Meco G., Alessandri A., Giustini P., Bonifati V. Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study. Mov. Disord. 12:1997;610-612.
39. Meltzer H.Y., Matsubara S., Lee J.C. Classification of typical and atypical antipsychotic drugs on the basis of D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251:1989;238-246.
40. Mintzer J., Yeung P., Mullen J., Sweitzer D. Extrapyramidal symptoms in elderly outpatients treated with either quetiapine or risperidone (poster). Presented at the Annual Meeting of the American Psychiatric Association, Chicago, Illinois, USA. 2000.
41. Mohr E., Mendis T., Hildebrand K., De Deyn P.P. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov. Disord. 15:2000;1230-1237.
42. Molho E.S., Factor S.A. Worsening of motor features of parkinsonism with olanzapine. Mov. Disord. 14:1999;1014-1016.
43. Molho E.S., Factor S.A. Parkinson's disease: the treatment of drug-induced hallucinations and psychosis. Curr. Neurol. Neurosci. Rep. 1:2001;320-328.
44. Moskovitz C., Moses III H., Klawans H.L. Levodopa-induced psychosis: a kindling phenomenon. Am. J. Psychiatry. 135:1978;669-675.
45. Ondo W.G., Levy J.K., Vuong K.D., Hunter C., Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov. Disord. 17:2002;1031-1035.
46. Parsa M.A., Bastani B. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. 10:1998;216-219.
47. Rich S.S., Friedman J.H., Ott B.R. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J. Clin. Psychiatry. 56:1995;556-559.
48. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J. Clin. Psychiatry. 60:(Suppl. 10):1999;5-14.
49. Rosebush P.I., Mazurek M.F. Neurologic side effects in neuroleptic-naïve patients treated with haloperidol or risperidone. Neurology. 52:1999;782-785.
50. Sajatovic M., Perez D., Brescan D., Ramirez L.F. Olanzapine therapy in elderly patients with schizophrenia. Psychopharmacol. Bull. 34:1998;819-823.
51. Samanta J., Stacy M. Quetiapine in the treatment of hallucinations in advanced Parkinson's disease. Mov. Disord. 13:(Suppl. 2):1998;274.
52. Schneider L., Yeung P., Sweitzer D., Arvanitis L. Effects of Seroquel (quetiapine) on reducing hostility and psychosis in patients with Alzheimer's disease (poster). Presented at the American Psychiatric Association Meeting, Washington D.C., USA. 1999.
53. Scholz E., Dichgans J. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur. Arch. Psychiatry Neurol. Sci. 235:1985;60-64.
54. Solomons K., Geiger O. Olanzapine use in the elderly: a retrospective analysis. Can. J. Psychiatry. 45:2000;151-155.
55. Stover N.P., Juncos J.L. Olanzapine treatment of parkinsonian patients with psychosis. Neurology. 52:(Suppl. 2):1999;A215.
56. Sweet R.A., Pollock B.G. New atypical antipsychotics. Experience and utility in the elderly. Drugs Aging. 12:1998;115-127.
57. Targum S.D., Criden M.R., Rubin A., Arvanitis L.A. Efficacy of Seroquel (quetiapine) in Parkinson's patients with psychosis. Mov. Disord. 12:1997;842.
58. Targum S.D., Abbott J.L. Efficacy of quetiapine in Parkinson's patients with psychosis. J. Clin. Psychopharmacol. 20:2000;54-60.
59. Tariot P.N., Salzman C., Yeung P.P., Pultz J., Rak I.W. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin. Ther. 22:2000;1068-1084.
60. Tarsy D., Baldessarini R.J., Tarazi F.I. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 16:2002;23-45.
61. The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet. 353:1999;2041-2042.
62. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N. Engl. J. Med. 340:1999;757-763.
63. Trosch R.M., Friedman J.H., Lannon M.C., Pahwa R., Smith D., Seeberger L.C., O'Brien C.F., LeWitt P.A., Koller W.C. Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Mov. Disord. 13:1998;377-382.
64. van Harten P.N., Kahn R.S. Tardive dystonia. Schizophr. Bull. 25:1999;741-748.
65. Weiden P.J., Mann J.J., Haas G., Mattson M., Frances A. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am. J. Psychiatry. 144:1987;1148-1153.
66. Weiner W.J., Minagar A., Shulman L. Olanzapine for the treatment of hallucinations/delusions in Parkinson's disease. Mov. Disord. 13:(Suppl. 2):1998;62.
67. Wolters E.C., Hurwitz T.A., Mak E., Teal P., Peppard F.R., Remick R., Calne S., Calne D.B. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology. 40:1990;832-834.
68. Wolters E.C., Jansen E.N., Tuynman-Qua H.G., Bergmens P.L. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology. 47:1996;1085-1087.
69. Workman R.H. Jr., Orengo C.A., Bakey A.A., Molinari V.A., Kunik M.E. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. 9:1997;594-597.
70. Zarate C.A. Jr., Baldessarini R.J., Siegel A.J., Nakamura A., McDonald J., Muir-Hutchinson L.A., Cherkerzian T., Tohen M. Risperidone in the elderly: a pharmacoepidemiologic study. J. Clin. Psychiatry. 58:1997;311-317.